Clinical Implications of Triple Combination Therapies(Metformin+Alpha-glucosidase Inhibitor+DPP-4 Inhibitor) in Type 2 Diabetes

Clinical Implications of Triple Combination Therapies(Metformin+Alpha-glucosidase Inhibitor+DPP-4 Inhibitor) in Type 2 Diabetes - Clinical Implications of Triple Combination Therapies(Metformin+Alpha-glucosidase Inhibitor+DPP-4 Inhibitor) in Type 2 Diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010061

Enrollment

Registered

2013-03-01

Start date

2012-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes mellitus

Interventions

Metformin+Anagliptin Miglitol+Anagliptin Metformin+Miglitol+Anagliptin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients with type 2 diabetes receiving either metformin and/or miglitol for at least two months before the start of the run-in period without any changes in the type or dosage of the drug 2.HbA1c(NGSP) is less than 8.0% more than 6.5% measured during the run-in period

Exclusion criteria

Exclusion criteria: 1.Patients require insulin or oral antidiabetic drug therapy other than metformin and/or miglitol 2.Female patients who were pregnant,suspected of being pregnant,planning a pregnancy,or lactating 3.Patients with,or a history of,serious renal disease(Serum Creatinine of >=2mg/dL 4.Any patients deemed by the investigator to be ineligible for participation in this study

Design outcomes

Primary

Measure	Time frame
Efficacy:HbA1c,Glyco-albumin,Fasting blood glucose,Serum lipid(TG,TC,LDL-C,HDL-C),Meal load test(Post prandial glucose,active-GLP-1,active-GIP,Ghrelin,PYY,Leptin),Body weight,Body fat percentage,amount of fat Safety:AE,clinical laboratory test	—

Countries

Japan

Contacts

Public ContactTakeshi Osonoi

Nakakinen Clinic Director

t-osonoi@kensei-kai.com029-353-2800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026